Near-term strategies for biotech drug developers facing shifting healthcare dynamics

A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.

Read the full article


Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”

Watch the full video

The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.

Return to Insights Center

Related Insights


Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021


New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023


Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023


What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024


Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023


8 things you need to know about eCTDs in China

Jul 1, 2022


Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021


Preparing for a new era in European Market Access

Jul 22, 2022


Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021


Assessing appropriate use of ECAs in clinical trials

May 28, 2023


Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021